Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.

Imfinzi (durvalumab) - AstraZeneca

Imjudo (tremelimumab-actl) - AstraZeneca

Yervoy (ipilimumab) - BMS

AiTan (rivoceranib) - Elevar Therapeutics

Tecentriq (atezolizumab) - Roche

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

sorafenib - Generic mfg.

Anniko (penpulimab-kcqx) - Akesobio, Sino Biopharm

Lenvima (lenvatinib) - Eisai, Merck (MSD)

Avastin (bevacizumab) - Roche

Keytruda (pembrolizumab) - Merck (MSD)

Cabometyx (cabozantinib tablet) - Exelixis

Focus V (anlotinib) - Advenchen

AiRuiKa (camrelizumab) - Elevar Therapeutics

Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials. (PubMed, World J Gastrointest Pharmacol Ther) - Sep 9, 2026 - "Our study compared the efficacy of the main first-line treatments recommended for unresectable HCC. While we were able to rank the magnitude of efficacy across these treatments, the intrinsic limitations of our methods (primarily the reconstruction of IPD and the indirect nature of the treatment comparisons) should be borne in mind."
Journal • Hepatocellular Cancer • Oncology • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42707851

Andrea Messori; Andrea Ossato; Elena Orlandi; Lorenzo Gasperoni; Luna Del Bono; Stefano Vecchia; Vera Damuzzo

Sep 9, 2026